Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB has called its annual general meeting for 21 May 2026 in Lund, Sweden, offering shareholders the option to participate either in person or via digital postal voting. Shareholders must be registered with Euroclear Sweden by 12 May and follow specified procedures for notification, proxy authorization, and, where applicable, voting rights registration through nominees.
The agenda includes adoption of the annual accounts, decisions on result allocation and discharge of liability for the board and CEO, and determinations on board and auditor composition and remuneration. The nomination committee proposes re-election of all current board members, including Magnus Persson as chairman, signaling a preference for continuity in the company’s governance and strategic direction.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company based in Lund, focusing on the development of antibody-based therapies. The company targets cancer and inflammatory diseases, positioning itself within the innovative biopharmaceutical sector and addressing unmet medical needs in these therapeutic areas.
Average Trading Volume: 2,235,369
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.03B
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.